Guardian Pharmacy Services, Inc.
NYSE:GRDN · New York Stock Exchange
+$0.17 today
Vol 0.48M · Avg 0.48M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $49.2M +169.3% | -$71.0M -288.3% | $37.7M -24.0% | $49.7M +75.3% | $28.3M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $22.3M +13.0% | $19.8M +8.4% | $18.2M +10.1% | $16.6M +0.2% | $16.5M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $3.1M | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $13.8M -89.5% | $131.5M +2259.1% | -$6.1M -80.1% | -$3.4M -125.9% | $13.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $6.4M +121.7% | -$29.4M -288.5% | $15.6M +183.3% | -$18.7M -1175.1% | -$1.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$8.6M +66.4% | -$25.5M -78.3% | -$14.3M +14.9% | -$16.8M -117.7% | -$7.7M | $592.6M | $1.3B | $626.2M |
| Inventory | -$877.0K +23.8% | -$1.2M -126.0% | $4.4M +154.5% | -$8.1M -3284.6% | -$240.0K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $16.4M +23.9% | $13.2M +110.2% | $6.3M -52.9% | $13.4M +36.7% | $9.8M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$586.0K +96.3% | -$16.0M -183.4% | $19.2M +367.5% | -$7.2M -117.5% | -$3.3M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $5.4M -23.9% | $7.1M +33.3% | $5.4M +21.7% | $4.4M +111.3% | $2.1M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $100.3M +73.0% | $58.0M -18.2% | $70.8M +46.0% | $48.5M -17.1% | $58.5M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$19.6M -19.6% | -$16.4M -12.4% | -$14.6M +13.2% | -$16.8M -80.7% | -$9.3M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 +100.0% | -$14.7M -1393.4% | -$985.0K +50.8% | -$2.0M +54.5% | -$4.4M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$12.7M -1989.7% | $671.0K -68.0% | $2.1M +140.3% | $874.0K +63.4% | $535.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$32.3M -6.1% | -$30.4M -126.2% | -$13.4M +24.9% | -$17.9M -36.1% | -$13.1M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$5.0M +86.3% | -$36.5M -1161.0% | -$2.9M -3.2% | -$2.8M +54.0% | -$6.1M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $27.4M -77.1% | $119.8M | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$29.0M +47.4% | -$55.2M | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 +100.0% | -$35.8M +7.0% | -$38.4M -24.7% | -$30.8M -77.5% | -$17.4M | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$497.0K +96.9% | -$16.0M -0.7% | -$15.9M -39.4% | -$11.4M +14.3% | -$13.3M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$7.1M +70.1% | -$23.6M +58.7% | -$57.2M -27.1% | -$45.0M -22.4% | -$36.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $61.0M +1459.9% | $3.9M +2595.2% | $145.0K +101.0% | -$14.4M -268.2% | $8.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $80.7M +94.1% | $41.6M -26.1% | $56.3M +77.2% | $31.8M -35.5% | $49.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$5.36B
10x Genomics, Inc.
NASDAQ:TXG
$4.44B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.83B
National HealthCare Corporation
AMEX:NHC
$3.00B
Nuvation Bio Inc.
NYSE:NUVB
$1.89B
Pediatrix Medical Group, Inc.
NYSE:MD
$1.89B
Mesoblast Limited
NASDAQ:MESO
$1.84B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.22B
QuidelOrtho Corporation
NASDAQ:QDEL
$901.48M
Janux Therapeutics, Inc.
NASDAQ:JANX
$851.95M
SEC Filings
Recent regulatory filings
No filings found.
Does GRDN generate free cash flow?
Guardian Pharmacy Services, Inc. (GRDN) generated $80.71M of free cash flow in fiscal 2025.
How much operating cash flow does GRDN produce?
Operating cash flow was $100.29M, before capital expenditures of $19.58M.
Explore More
Continue the stock analysis
Jump to another research area for this company.